GlassScriptPhysician profile
Tara Bozek
NPI 1144751892
$7,300.18
in general payments reported to CMS, 2019-2025
42 companies · $1,319 in 2025
The $1,319 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,525 · 2022: $1,731 · 2023: $1,210 · 2024: $1,514 · 2025: $1,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,043.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,006.07 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $952.61 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $762.55 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $639.66 | 2021-2025 | |
| Glaxosmithkline, LLC. | $567.70 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $383.17 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $372.62 | 2021-2025 | |
| Abbott Laboratories | $309.51 | 2021-2025 | Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.86 | 2021-2024 | Spiriva Respimat, Jardiance |
| Amgen INC. | $210.97 | 2021-2025 | Repatha, Otezla, Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $164.37 | 2022-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $163.97 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $158.16 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Sanofi-Aventis U.S. LLC | $150.89 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.22 | 2021-2025 | Xifaxan |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Bozek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.